To test our hypothesis, we not only assessed the correlation between the expression of the newly identified JAK3-INSL3 fusion transcript with clinical data from SS patients, but also conducted in vitro and in vivo experiments with established CTCL cell lines. This evidence concerns the gene JAK3 and primary cutaneous T-cell non-Hodgkin lymphoma.